The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid shifting sentiment in the emerging biotech sector, Industrial Alliance Securities has lowered its price target for MediWound from $25.00 to $22.00. The company reported a Q1 loss of $0.23 per share on revenue of $1.48 million, missing consensus analyst estimates. Despite the quarterly shortfall, management reaffirmed its full-year 2026 revenue guidance, maintaining a target range between $24 million and $26 million.
Sign in to access this content
Sign InThis adjustment comes as investors scrutinize small-cap biotech performance, with MDWD facing headwinds relative to its industry peers. Per market data, the downward revision reflects concerns over the extended timeline for the EscharEx Phase III study, mirroring cautious trends seen in peers like Vericel Corporation, which recently reported moderate revenue growth. Nevertheless, the new $22 target still implies significant projected upside from current valuation levels.
MDWD remains at a pivotal technical level as of the close on May 29, 2026, with traders looking for clinical updates to serve as a catalyst. On the macro front, investors should note the US CB Consumer Confidence data from May 26, which printed at 93.1, influencing overall risk appetite for growth stocks. The reaffirmed annual revenue guidance of $24-$26 million remains the primary benchmark for assessing management's recovery trajectory in the coming quarters.